Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01946165 · ClinicalTrials.gov registry record · Phase 2
Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT01946165: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01946165 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 69 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01946165, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if adding the combination of abiraterone acetate and prednisone with or without enzalutamide to hormonal therapy can help to control prostate cancer when given before surgery. The safety of the drug combination will also be studied.
Interventions
- DRUG Prednisone
- DRUG Enzalutamide
- DRUG Abiraterone Acetate
- DRUG LHRHa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2013-10-31 |
| Est. Completion | 2017-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01946165
The ClinicalTrials.gov registry entry for NCT01946165 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Prednisone is the first listed.
NCT01946165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01946165 about?
NCT01946165 is a clinical study titled "Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide". The goal of this clinical research study is to learn if adding the combination of abiraterone acetate and prednisone with or without enzalutamide to hormonal therapy can help to control prostate cancer when given before surgery. The safety of the drug combination will also be studied.
What is the current status of trial NCT01946165?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2013-10-31. Estimated completion is 2017-07-28.
What interventions are being tested in trial NCT01946165?
The interventions under investigation include: Prednisone (DRUG), Enzalutamide (DRUG), Abiraterone Acetate (DRUG), LHRHa (DRUG).
Who is sponsoring clinical trial NCT01946165?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.